Trial Profile
A Phase I Trial of VS-6766 (RO5126766) (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With Everolimus
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Avutometinib (Primary) ; Everolimus
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Gynaecological cancer; Lung cancer; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; Proof of concept
- Acronyms RAF/MEK
- 12 Jul 2023 Planned End Date changed from 1 Feb 2023 to 1 May 2024.
- 12 Jul 2023 Planned primary completion date changed from 1 Feb 2023 to 1 May 2024.
- 03 Feb 2023 According to a Verastem Oncology Media Release, company plan to present updated results of KRAS-mutant NSCLC.